State Street SPDR S&P Pharmaceuticals ETF (XPH) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores XPH 4.8 out of 10 — highest on Value (10.0), lowest on Quality (1.7). It trades at 15.4 times earnings, against its own median of 18.8. Its ten largest holdings are 23% of the fund.
What stands out in XPH's data
U.S. pharmaceutical companies, selected for quality traits.
Trades at a cheaper price than most pharma peers — less of each dollar goes to the purchase price.
Trailing EBITDA multiple of 10.0x sits 39% below the peer median of 16.5x. Holds 62 stocks.
A quality tilt on pharma, built for resilience in a health-care allocation.
Why did XPH move this week? It rose 1.6% in the week to October 9, 2026 — Pacira Biosciences and Xeris Biopharma drove it
XPH rose 1.6% in the week to October 9, 2026. The holdings that moved it most were Pacira Biosciences (+44.0%), Xeris Biopharma (+15.4%) and Veradermics (+12.1%); Enliven Therapeutics (−12.8%) pushed the other way.
How is XPH rated? ETF Copilot scores State Street SPDR S&P Pharmaceuticals ETF (XPH) 4.8 out of 10
As of October 9, 2026, ETF Copilot scores State Street SPDR S&P Pharmaceuticals ETF (XPH) 4.8 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 4.8 / 10
- Growth: 5.8 / 10
- Value: 10.0 / 10
- Risk: 3.3 / 10
- Quality: 1.7 / 10
- Return: 3.5 / 10
Is XPH expensive right now? It trades at 15.4 times earnings, against its own median of 18.8
As of October 9, 2026, XPH is cheaper than 81% of its own last 6 years.
Trailing 12 months, built from XPH's holdings. How we calculate this →
What's inside XPH?
What's inside XPH: Size (Large 12%, Mid 19%, Small 70%); Geography (International 4%, US 96%).
What are XPH's top holdings? The ten largest are 23% of the fund
Xeris Biopharma, Veradermics, Pacira Biosciences, Amneal Pharmaceuticals, Viatris, Eli Lilly, Corcept Therapeutics, Ligand Pharmaceuticals, Indivior Pharmaceuticals and ANI Pharmaceuticals are XPH's largest holdings, in that order.
Less concentrated than 80% of Health & Biotech ETFs.
Half of XPH's weight sits in its 24 largest positions, and once those weights are taken into account it behaves like 56 equally weighted holdings.
What is XPH's expense ratio? 0.35% a year
As of October 9, 2026, XPH charges 0.35% a year, yields 0.42% and holds $462M in assets across 62 positions.
| Measure | XPH |
|---|---|
| Expense ratio | 0.35% |
| Dividend yield | 0.42% |
| Assets under management | $462M |
| Holdings | 62 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “State Street SPDR S&P Pharmaceuticals ETF (XPH) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/xph
ETF Copilot Pro unlocks XPH's price and what each holding weighs.
Try Pro free →